As an infectious disease epidemiologist, Dr. Moise Desvarieux has had two research foci covering the traditional field of infectious disease epidemiology and the newer interface of infectious and chronic diseases. Throughout his career, he has served as Principal Investigator or co-Principal Investigator of seven externally funded research grants. Five of these grants have been funded by NIH, and one by CDC. Notably, Dr. Desvarieux is the PI of the INVEST study, and works collaboratively with colleagues in the Department of Neurology at P&S and the School of Dentistry on this large multi-ethnic cohort of participants in Northern Manhattan aiming to assess the contribution of chronic periodontal infections to vascular disease. Dr. Desvarieux has published in Lancet, the American Journal of Public Health, Stroke, Circulation, the Journal of Infectious Diseases, and Atherosclerosis, among others. In 2005, he was awarded a Chair of Excellence by the French National Agency for Research in collaboration with Inserm to coordinate the study of oral infections and vascular disease in the 5 cohorts of INVEST in the US, SHIP in Germany, PRIME in Ireland, HAPIEE in Poland and WHO-Monica in France. In November 2005, he also received the "Leadership in Research" award from the Friends of the National Institute of Dental and Craniofacial Research at the National Press Club in Washington for "outstanding scientific contribution". Dr. Desvarieux teaches the "Epidemiology of Cardiovascular Disease" course at Columbia.
MD, 1986, Faculte de Medecine, Universite d'Etat d'Haiti
Honors and Awards:
Chair of Excellence, Institut de la Sante et de la Recherche Medicale (INSERM), 2005
Leadership in Research Award, Friends of the National Institute of Dental and Craniofacial Research, NIH, 2005
Selected by the French Ministry of Health as International Jury Member charged with recommending new national Hepatitis B vaccination policy for France, 2003
Nominated by the University of Minnesota to the Howard Hughes Investigator National competition, Howard Hughes Research Institute, United States, 2000
Selected New York City Activities:
Oral Infections and Vascular Disease Epidemiology Study (INVEST)
This project aims to assess and quantify the role of chronic oral infections in the progression of atherosclerosis and vascular disease in the tri-ethnic population of Northern Manhattan. 1056 subjects were randomly selected from Northern Manhattan and are being followed with an extensive infectious and inflammatory profile related to their periodontal infections and an evaluation of their vascular status (atherosclerosis, heart attacks, stroke) over a period of 10 years.
Selected Global Activities:
International Training Research and Exchange Program in Infectious Disease Epidemiology (INTREPIDE)
This unique program combines resources of faculty at the French Institut de Medecine et D'Epidemiologie Appliquee (IMEA), the University of Paris, the Pasteur Institute, the University of Montpellier, the French Institute for Research and Development to offer research platforms and attack the global problems of infectious diseases on a global front. INTREPIDE faculty lead cutting-edge research on malaria (through the French National Reference Center for Malaria), HIV and SIV (through their laboratories and platforms) and on other important diseases; they host students and researchers in their platforms in Senegal, Cameroon, Egypt, Brazil, France, and other countries.
Countries: Benin; Brazil; Cameroon; Egypt; France; Haiti; Martinique; Senegal
International Network for Oral Infections, Vascular Disease and Atherosclerosis in Transatlantic and European Cohorts (INNOVATE)
Dr Desvarieux was awarded a Chair of Excellence to coordinate a unique collaboration to initiate the standardization of protocols between investigators in five countries determined to join forces to tackle the question of the contribution of chronic oral infections to atherosclerosis and vascular diseases. The five cohorts of INNOVATE are INVEST in New York; WHO-MONICA in Toulouse, France; PRIME in Belfast, Ireland; SHIP in Greifswald, Germany; and HAPIEE in Krakow, Poland.
Countries: France; Germany; Ireland; Poland
Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Sacco RL, Papapanou PN Periodontal Microbiota and Carotid Intima-Media thickness: The Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 111 576-582 2005
Desvarieux M, Schwahn C, Volzke H, Demmer R T, Ludemann J, Kellsler C, Jacobs DR Jr, Ulrich J, Kocher T Gender Differences in the Relationship Between Periodontal Disease, Tooth Loss and Atherosclerosis Stroke 35 2029-2035 2004
Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Papapanou PN, Sacco RL Relationship Between Periodontal Disease, Tooth Loss and Carotid Artery Plaque: The Oral Infections and Vascular Disease Epidemiology Study (INVEST) Stroke 34 2120-2125 2003
Folsom AR, Desvarieux M, Nieto FJ, Boland LL, Ballantyne CM, Chambless LE B vitamin status and inflammatory markers Atherosclerosis 169 169-174. 2003
Desvarieux M, Landman R, Liautaud B, Girard PM. Eyes wide open or eyes wide shut? Anti-retroviral therapy in resource-poor countries: Illusions and Realities American Journal of Public Health 95 8-13 2005
Pacanowski J, Develioglu L, Kamga I, Sinet M, Desvarieux M, Girard PM, Hosmalin A. Early plasmacytoid dendritic cell changes predict plasma HIV rebound in primary infection J Infect Dis 190 1889-92 2004
Desvarieux M. Periodontal disease, race and vascular disease Compend Contin Educ Dent 22 34-41 2001
Desvarieux M, Pape JW, Hyppolite PR, Johnson WD Jr. A novel approach to treatment of tuberculosis in an HIV-endemic area Am J Public Health 91 138-141. 2001
Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson Fr WD, Pape JW Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial Lancet 356 1470-1474. 2000
Susser E, Desvarieux M, Wittkowski K Reporting sexual risk behavior for HIV: A practical risk index and a method for improving risk indices Am J Public Health 88 671-674 1998